Study Comparing Immune Response to Two Pneumococcal Vaccination Methods in Adults Treated for Lymphoma

What this Trial Is About

Researchers are investigating the immune response to pneumococcal vaccination strategies in adults treated for lymphoma and acute leukemia. The study compares the traditional two-step vaccination approach using a 13-valent conjugate vaccine PCV13 followed by a 23-valent polysaccharide vaccine PPV23 against a newer guideline recommending a single injection of PREVENAR20. These patients often have weakened immune systems due to chemotherapy, increasing their risk for pneumococcal invasive diseases, but the effectiveness of these vaccination strategies in this group is not well documented. The trial includes two groups one group of 80 patients received PCV13 followed by PPV23 at least two months later, and another group of 80 patients will receive a single PREVENAR20 injection. The study monitors immune responses at multiple points, including before vaccination, four weeks after each vaccine injection, and up to 14 months post-vaccination. Researchers measure specific antibodies and immune activity to evaluate how well each vaccination method prompts an immune response. Participants will undergo blood tests at several time points to measure pneumococcal antibody levels and immune activity. The study also assesses vaccine safety, looking for local or general reactions and any invasive pneumococcal infections. Researchers aim to identify factors that predict poor response to vaccination by comparing patient demographics, biological data, and treatments received. The total follow-up period extends to 14 months after vaccination to assess the durability of the immune response.

Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma